# TheraSphere With Durvalumab and Tremelimumab for HCC

> **NCT05063565** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** TheraSphere Y-90 glass microsphere therapy
- **DRUG:** Durvalumab (Imfinzi) immunotherapy
- **DRUG:** Tremelimumab immunotherapy

## Key facts

- **NCT ID:** NCT05063565
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-03
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063565, "TheraSphere With Durvalumab and Tremelimumab for HCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05063565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*